AN INSIGHT INVESTIGATION ON STEADY-STATE PHARMACOKINETICS OF LOBEGLITAZONE-LOADED DISSOLVING MICRONEEDLES IN RATS

Authors

  • SUKANTA ROY Department of Pharmaceutics, School of Pharmacy, The Neotia University, West Bengal, India. https://orcid.org/0000-0003-2694-4045
  • DIBYA DAS Department of Pharmaceutical Technology, JIS University, Kolkata, India.
  • JAYANTA KUMAR CHAUDHURY Department of Pharmaceutical Technology, JIS University, Kolkata, India. https://orcid.org/0009-0007-5973-9386
  • KAMALAKANTA RAY Department of Pharmaceutical Technology, JIS University, Kolkata, India.
  • SOUMIK LAHA Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, Barasat, Kolkata, West Bengal, India. https://orcid.org/0009-0007-0238-4414
  • SUBAS CHANDRA DINDA Department of Pharmaceutics, School of Pharmacy, The Neotia University, West Bengal, India
  • ANIRBANDEEP BOSE Department of Pharmaceutics, BCDA College of Pharmacy and Technology, Hridaypur, Barasat, Kolkata, West Bengal, India.

DOI:

https://doi.org/10.22159/ajpcr.2025v18i9.55996

Keywords:

Dissolving microneedles, Lobeglitazone, Steady-state pharmacokinetics, Transdermal delivery, Type 2 diabetes mellitus

Abstract

Objectives: This study aimed to investigate the steady-state pharmacokinetics of lobeglitazone administered through a dissolving microneedle array (DMNA) compared to conventional oral delivery in rats, addressing limitations such as first-pass metabolism and fluctuating plasma concentrations associated with oral therapy.

Methods: Lobeglitazone-loaded DMNAs were fabricated using a micromolding technique with polyvinylpyrrolidone K90 and hyaluronic acid. Structural characteristics were confirmed through SEM. Male Wistar rats were divided into two groups (n=6): oral and DMNA (0.5 mg/day for 7 days). Plasma samples were collected over a period of 216 h and analyzed using a validated liquid chromatography–mass spectrometry/mass spectrometry method. Pharmacokinetic parameters, including Cmin,ssCmax, Tmax, AUC, kel, T1/2, and mean residence time (MRT), were determined by non-compartmental analysis.

Results: DMNA administration resulted in significantly enhanced systemic exposure (AUC168–216: 26072.26±1510.30 ng·h/mL vs. 13658.04±1659.16 ng·h/mL, p<0.00001), prolonged half-life (10.05±0.68 h vs. 6.16±0.55 h), and a higher MRT (14.51±0.98 h vs. 8.88±0.80 h). The DMNA group maintained stable plasma concentrations with reduced fluctuation between peak and trough levels, indicating effective steady-state achievement and sustained drug release compared to oral delivery.

Conclusion: Dissolving microneedle-based transdermal delivery of lobeglitazone offers a superior pharmacokinetic profile over oral administration, supporting its potential in improving long-term glycemic control. Further studies are warranted to confirm efficacy and safety in clinical settings.

Downloads

Download data is not yet available.

References

1. Jang JY, Bae H, Lee YJ, Choi YI, Kim HJ, Park SB, et al. Structural basis for the enhanced anti-diabetic efficacy of lobeglitazone on PPARγ. Sci Rep. 2018;8(1):31. doi: 10.1038/s41598-017-18274-1, PMID 29311579

2. Lee HW, Kim BY, Ahn JB, Kang SK, Lee JH, Shin JS, et al. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem. 2005;40(9):862-74. doi: 10.1016/j.ejmech.2005.03.019, PMID 15908051

3. Jung JA, Lee SY, Kim TE, Kim JR, Kim C, Huh W, et al. Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin. Drug Des Dev Ther. 2015;9:737-43. doi: 10.2147/DDDT.S76591, PMID 25767371

4. Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, et al. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-gamma agonist: A single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin Ther. 2011;33(11):1819-30. doi: 10.1016/j. clinthera.2011.09.023, PMID 22047812

5. Davit B, Braddy AC, Conner DP, Yu LX. International guidelines for bioequivalence of systemically available orally administered generic drug products: A survey of similarities and differences. AAPS J. 2013;15(4):974-90. doi: 10.1208/s12248-013-9499-x, PMID 23821352

6. Park MK, Kim TE, Kim J, Kim C, Yoon SH, Cho JY, et al. Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014;34(7):467-74. doi: 10.1007/s40261-014-0197-y, PMID 24802657

7. Mdanda S, Ubanako P, Kondiah PP, Kumar P, Choonara YE. Recent advances in microneedle platforms for transdermal drug delivery technologies. Polymers (Basel). 2021;13(15):2405. doi: 10.3390/ polym13152405, PMID 34372008

8. Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety. Drug Deliv. 2010;17(4):187-207. doi: 10.3109/10717541003667798, PMID 20297904

9. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-8. doi: 10.1038/nbt.1504, PMID 18997767

10. Jung JH, Jin SG. Microneedle for transdermal drug delivery: Current trends and fabrication. J Pharm Investig. 2021;51(5):503-17. doi: 10.1007/s40005-021-00512-4, PMID 33686358

11. Zhang J, Li H, Albakr L, Zhang Y, Lu A, Chen W, et al. Microneedle-enabled therapeutics delivery and biosensing in clinical trials. J Control Release. 2023;360:687-704. doi: 10.1016/j.jconrel.2023.07.023, PMID 37442203

12. Moawad F, Pouliot R, Brambilla D. Dissolving microneedles in transdermal drug delivery: A critical analysis of limitations and translation challenges. J Control Release. 2025;383:113794. doi: 10.1016/j.jconrel.2025.113794, PMID 40319916

13. Oliveira C, Teixeira JA, Oliveira N, Ferreira S, Botelho CM. Microneedles’ device: Design, fabrication, and applications. Macromol. 2024;4(2):320-55. doi: 10.3390/macromol4020019

14. Mudaliar S, Sharma S. Quantification of lobeglitazonesulfate in bulk and tablet dosage form by a validated UV spectroscopy method: A new thiazolidinedione antidiabetic drug. Drug Metab Bioanal Lett. 2024;17(2):49-55. doi: 10.2174/0118723128319462240614111627, PMID 40296487

15. Mukherjee K, Roy S, Giri TK. Effect of intragranular/extragranulartara gum on sustained gastrointestinal drug delivery from semi-IPN hydrogel matrices. Int J Biol Macromol. 2023;253(5):127176. doi: 10.1016/j.ijbiomac.2023.127176, PMID 37783254

16. Lee JH, Yang SH, Oh JM, Lee MG. Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: Comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol. 2010;62(1):1-23. doi: 10.1211/jpp.62.01.0001, PMID 20722995

17. King MJ, Badea I, Solomon J, Kumar P, Gaspar KJ, Foldvari M. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther. 2002;4(4):479-88. doi: 10.1089/152091502760306562, PMID 12396742

18. Das D, Halder D, Bose A, Shaw TK, Saha C, Kumar De P, et al. Determination of metformin and sitagliptin in healthy human volunteers’ blood plasma and its bioequivalence study under fasting condition. Int J Appl Pharm. 2022;14(6):42-50. doi: 10.22159/ ijap.2022v14i6.45140

19. Ng LC, Gupta M. Transdermal drug delivery systems in diabetes management: A review. Asian J Pharm Sci. 2020;15(1):13-25. doi: 10.1016/j.ajps.2019.04.006, PMID 32175015

20. Ita K. Transdermal delivery of drugs with microneedles-potentialand challenges. Pharmaceutics. 2015;7(3):90-105. doi: 10.3390/ pharmaceutics7030090, PMID 26131647

21. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16(8):915-20. doi: 10.1038/nm.2182, PMID 20639891

22. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547-68. doi: 10.1016/j. addr.2012.04.005, PMID 22575858

23. Ripolin A, Quinn J, Larrañeta E, Vicente-Perez EM, Barry J, Donnelly RF. Successful application of large microneedle patches by human volunteers. Int J Pharm. 2017;521(1-2):92-101. doi: 10.1016/j. ijpharm.2017.02.011, PMID 28216463

24. Larrañeta E, Lutton RE, Woolfson AD, Donnelly RF. Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development. Mater Sci Eng R Rep. 2016;104:1-32. doi: 10.1016/j.mser.2016.03.001

25. Zhang Y, Yu J, Kahkoska AR, Wang J, Buse JB, Gu Z. Advances in transdermal insulin delivery. Adv Drug Deliv Rev. 2019 Jan 15;139:51-70. doi: 10.1016/j.addr.2018.12.006, PMID 30528729

Published

07-09-2025

How to Cite

SUKANTA ROY, et al. “AN INSIGHT INVESTIGATION ON STEADY-STATE PHARMACOKINETICS OF LOBEGLITAZONE-LOADED DISSOLVING MICRONEEDLES IN RATS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 18, no. 9, Sept. 2025, pp. 104-10, doi:10.22159/ajpcr.2025v18i9.55996.

Issue

Vol 18 Issue 9 September 2025

Section

Original Article(s)

Copyright (c) 2025 Sukanta Roy, Dibya Das, Jayanta Kumar Chaudhury, Kamalakanta Ray, Soumik Laha, Anirbandeep Bose, Subas Chandra Dinda

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.